The US and China Jiahe announced that Guangzhou Taihe Cancer Hospital, a subsidiary of the company, was approved by the Guangdong Provincial Health Commission and the Guangdong Drug Administration to enter the list of designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area on December 8, 2025. This move has made the company a professional oncology medical institution qualified to use innovative drugs in Hong Kong and Macao. It can introduce and use urgently needed drugs in the field of oncology that have already been listed in Hong Kong and Macao and have not yet been approved domestically, further broadening business boundaries and forming a differentiated competitive advantage with the market.

The US and China Jiahe announced that Guangzhou Taihe Cancer Hospital, a subsidiary of the company, was approved by the Guangdong Provincial Health Commission and the Guangdong Drug Administration to enter the list of designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area on December 8, 2025. This move has made the company a professional oncology medical institution qualified to use innovative drugs in Hong Kong and Macao. It can introduce and use urgently needed drugs in the field of oncology that have already been listed in Hong Kong and Macao and have not yet been approved domestically, further broadening business boundaries and forming a differentiated competitive advantage with the market.